Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05835609 | PM534 Administered Intravenously to Patients With Advanced Solid Tumors | recruiting | Phase 1 | 30 | PharmaMarINDUSTRY | 1 | Aug 22, 2025 | clinicaltrials |
| NCT07056556 | A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors | recruiting | Phase 1 | 31 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 22, 2025 | clinicaltrials |
| NCT07135128 |
| A Clinical Study of [225Ac]Ac-FAPI-XT(XT117) Injection in Patients With Advanced Solid Tumors |
| recruiting |
| Phase 1 |
| 20 |
| Xiaorong SunOTHER |
| 1 |
| Aug 21, 2025 |
| clinicaltrials |
| NCT06907043 | A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.(EIK1004-001) | recruiting | Phase 1 / Phase 2 | 130 | Eikon TherapeuticsINDUSTRY | 3 | Aug 19, 2025 | clinicaltrials |
| NCT05725291 | AMT-116 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 80 | Multitude Therapeutics Inc.INDUSTRY | 3 | Aug 17, 2025 | clinicaltrials |
| NCT05761223 | A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849 | recruiting | Phase 1 / Phase 2 | 151 | 1ST Biotherapeutics, Inc.INDUSTRY | 1 | Aug 17, 2025 | clinicaltrials |
| NCT06487455 | A Clinical Study of SPH7485 Tablets in the Treatment of Advanced Solid Tumors. | recruiting | Phase 1 | 170 | Shanghai Pharmaceuticals Holding Co., LtdINDUSTRY | 1 | Aug 17, 2025 | clinicaltrials |
| NCT06822998 | HF50 in HER-2 Positive and Low-expression Advanced Solid Tumors(HF50) | recruiting | Early Phase 1 | 10 | HighField Biopharmaceuticals CorporationINDUSTRY | 1 | Aug 17, 2025 | clinicaltrials |
| NCT05906862 | AMT-253 in Patients With Selected Advanced Solid Tumours | recruiting | Phase 1 | 54 | Multitude Therapeutics (Australia) Pty LtdINDUSTRY | 1 | Aug 14, 2025 | clinicaltrials |
| NCT01166009 | CIBMTR Research Database | recruiting | — | 99,999,999 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Aug 12, 2025 | clinicaltrials |
| NCT07070349 | A Trial of HRS-6213 in Healthy Subjects and Patients With Solid Tumors | recruiting | Phase 1 / Phase 2 | 48 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 12, 2025 | clinicaltrials |
| NCT05836948 | The Clinical Study of SHR-9839 for Injection in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 174 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 11, 2025 | clinicaltrials |
| NCT07114627 | Impact of CES1 Genotype on Capecitabine Exposure in Cancer Patients(ESCAPE) | recruiting | — | 66 | Erasmus Medical CenterOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT06375564 | Clinical Evaluation of 177Lu-AB-3PRGD2 in Various Solid Tumors With Integrin αvβ3 Positive Expression | recruiting | Phase 1 | 20 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT07100249 | A Study of HDM2012 in Patients With Advanced Solid Tumor | recruiting | Phase 1 | 129 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 8, 2025 | clinicaltrials |
| NCT07110883 | A Clinical Study of SYS6023 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 400 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 1 | Aug 8, 2025 | clinicaltrials |
| NCT04778839 | Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors. | recruiting | Phase 1 | 98 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT07107633 | A Phase II Clinical Study to Evaluate the Efficacy and Safety of Technetium [99mtc]-H7ND Injection in the Diagnosis of Peritoneal Metastasis of Gastrointestinal Malignant Tumor. | recruiting | Phase 2 | 90 | Jiaxing Pharmadax Genesis Pharmaceutical Technology Co.,Ltd.OTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT06463340 | Study of SGR-3515 In Participants With Advanced Solid Tumors. | recruiting | Phase 1 | 52 | Schrödinger, Inc.INDUSTRY | 2 | Aug 1, 2025 | clinicaltrials |
| NCT07098052 | A Study of HDM2020 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 60 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 1, 2025 | clinicaltrials |
| NCT06484556 | T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor | recruiting | Phase 1 | 9 | Tao ZhangOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT06543056 | A Study of ES014 in Subjects With Advanced Solid Tumors | recruiting | Phase 2 | 15 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT07092748 | A Phase Ia/ Ib Study of HS387 in Subjects With Advanced Solid Tumors | recruiting | Phase 1 | 110 | Zhejiang Hisun Pharmaceutical Co. Ltd.INDUSTRY | 1 | Jul 30, 2025 | clinicaltrials |
| NCT06220838 | Study SC-101 in Subjects With Advanced Malignancies | recruiting | Phase 1 | 100 | Tianjin ConjuStar Biologics Co., Ltd.INDUSTRY | 1 | Jul 29, 2025 | clinicaltrials |
| NCT06710158 | Study of SC-102 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 120 | Tianjin ConjuStar Biologics Co., Ltd.INDUSTRY | 1 | Jul 29, 2025 | clinicaltrials |
| NCT07058207 | Weight Management in Obese Cancer Patients During Curative Active Treatment(CANOBESE) | recruiting | N/A | 50 | Institut d'Investigació Biomèdica de BellvitgeOTHER | 1 | Jul 28, 2025 | clinicaltrials |
| NCT05035745 | Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START) | recruiting | Phase 1 / Phase 2 | 63 | National University Hospital, SingaporeOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT05491083 | Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer(ComPACT) | recruiting | Phase 1 / Phase 2 | 51 | National University Hospital, SingaporeOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT06208410 | A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors | recruiting | Phase 1 / Phase 2 | 306 | Risen (Suzhou) Pharma Tech Co., Ltd.INDUSTRY | 1 | Jul 25, 2025 | clinicaltrials |
| NCT05217693 | A First-in-human of Multiplle Doses of BB-1705 in Subjects With Locally Advanced/Metastatic Solid Tumors | recruiting | Phase 1 | 288 | Bliss Biopharmaceutical (Hangzhou) Co., LtdINDUSTRY | 1 | Jul 24, 2025 | clinicaltrials |
| NCT05978102 | A Dose Escalation and Dose Expansion Clinical Study of STI-7349 in Subjects With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 183 | The Fourth Affiliated Hospital of Zhejiang University School of MedicineOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT03772561 | Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies(MEDIPAC) | recruiting | Phase 1 | 40 | National University Hospital, SingaporeOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT05701709 | Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 395 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 22, 2025 | clinicaltrials |
| NCT06666270 | Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 30 | Hangzhou SynRx Therapeutics Biomedical Technology Co., LtdINDUSTRY | 1 | Jul 20, 2025 | clinicaltrials |
| NCT06929663 | A Study of AK146D1 for Injection in the Treatment of Advanced Solid Tumors | recruiting | Phase 1 | 48 | AkesoINDUSTRY | 1 | Jul 17, 2025 | clinicaltrials |
| NCT05881525 | NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors | recruiting | Phase 1 | 18 | TCRCure Biopharma Ltd.INDUSTRY | 1 | Jul 16, 2025 | clinicaltrials |
| NCT07046702 | 68Ga-MY6349 PET/CT in Solid Tumors | recruiting | — | 300 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT06993870 | Phase I Study of HBT-708 for Patients With Advanced Solid Tumors | recruiting | Phase 1 | 60 | Shenyang Sunshine Pharmaceutical Co., LTD.INDUSTRY | 1 | Jul 11, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT06277219 | A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)(LIGHTSPEED-1) | recruiting | Phase 1 / Phase 2 | 150 | Latticon Antibody Therapeutics, IncINDUSTRY | 2 | Jul 8, 2025 | clinicaltrials |
| NCT07050641 | Phase I/II Study of SCTB39-1 in Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 110 | Sinocelltech Ltd.INDUSTRY | 1 | Jul 4, 2025 | clinicaltrials |
| NCT07050459 | A Phase I Study of SIM0686 in Participants With Locally Advanced/Metastatic Solid Tumors | recruiting | Phase 1 | 220 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 3, 2025 | clinicaltrials |
| NCT06669117 | FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations | recruiting | Phase 1 / Phase 2 | 140 | Pierre Fabre MedicamentINDUSTRY | 9 | Jul 2, 2025 | clinicaltrials |
| NCT06410131 | Study in Patients With Advanced Solid Tumors to Evaluate the Safety of FTL008.16 | recruiting | Phase 1 | 68 | Sound Biopharmaceuticals Ltd.INDUSTRY | 1 | Jul 1, 2025 | clinicaltrials |
| NCT06415487 | ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR) | recruiting | Phase 1 | 30 | Acepodia Biotech, Inc.INDUSTRY | 2 | Jul 1, 2025 | clinicaltrials |
| NCT07045454 | A Study of MHB118C Injection in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 200 | Minghui Pharmaceutical (Hangzhou) LtdINDUSTRY | 1 | Jul 1, 2025 | clinicaltrials |
| NCT06163391 | A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic Cancer | recruiting | Phase 1 | 40 | SOTIO Biotech AGINDUSTRY | 5 | Jun 29, 2025 | clinicaltrials |
| NCT03175224 | APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors(SPARTA) | recruiting | Phase 2 | 497 | Apollomics Inc.INDUSTRY | 11 | Jun 27, 2025 | clinicaltrials |
| NCT05481502 | An Exploratory Study to Evaluate Immune Determinants of the Response to Adoptive Cell Therapy (ACT) in Solid and Hematologic Tumors(PIONEER) | recruiting | N/A | 160 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Jun 24, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Aug 22, 2025source: clinicaltrials